FDA-Cleared Therapy for Pediatric Sleep Apnea From Vivos Offers Parents and Providers New Hope

FDA ‌Clears Revolutionary Non-Surgical Treatment for Pediatric Sleep Apnea

New Hope for Parents and Providers as Vivos therapeutics offers a Safe and Effective Option

[City, State] – A groundbreaking new treatment for pediatric obstructive sleep apnea (OSA) has received FDA clearance, offering a much-needed non-surgical option for children struggling with this⁣ common ‌yet ‌often overlooked condition. ​Vivos‌ Therapeutics, a leader ‌in innovative sleep ‌medicine, announced the FDA 510(k) ⁢clearance for its proprietary technology, marking a significant advancement in pediatric healthcare.

“Our technology represents ⁢the first FDA-cleared, highly effective, non-surgical alternative for kids aged 6 to 17 with ‍moderate to severe OSA,”⁣ said Kirk Huntsman, CEO of Vivos ⁤Therapeutics.

The overlap ‌between OSA and other ⁤childhood challenges like ADHD underscores the critical⁢ need for early and accurate diagnosis followed by effective ⁣treatment.

“Unfortunately, ‌too many pediatricians and family physicians fail to consider ‍breathing and sleep disorders when evaluating a child with common challenges,” emphasizes Huntsman. “Early intervention with our ⁢technology can​ not only restore a child’s ability to thrive at home and school but can⁢ also improve⁤ their odds​ of a lifetime of⁤ breathing freely and sleeping ⁤deeply.”

Spotting the Hidden⁤ Signs of Pediatric OSA

Children experience OSA differently than adults, with ‍distinct⁢ risk factors and symptoms. Unlike adults, whose OSA is often linked to obesity or unhealthy habits, children are​ more likely to develop ‍the condition due to ‍enlarged tonsils or adenoids, making prevention especially⁢ challenging.Understanding these differences is crucial‍ to identifying and addressing OSA‍ early, paving the way for proper treatment. Common symptoms of OSA in children include:

ADHD symptoms
Snoring
Mouth breathing
Pauses ​in ​breathing
Restless sleep / Frequent arousals
Snorting, gasping, coughing or choking
Night terrors
Nighttime sweating
⁣Bed-wetting

The Lifelong Impact of ⁤Early OSA Treatment in Children

Early intervention in ​treating⁢ pediatric OSA offers a pathway to lasting health improvements. Research has shown that effective treatment can lead to significant reductions in ADHD symptoms ⁣within just 2 to 6 months.

Treatment has ‍also been​ linked to:

Improved Cognitive Function: Better oxygenation during ⁣sleep enhances brain progress,⁢ aiding memory and learning.
Better Academic Performance: Quality sleep fosters improved focus, attention, and ⁤engagement in ⁤the ⁤classroom.
Reduced Health Risks: Proper airway ​function lowers the likelihood⁤ of developing chronic conditions such as ⁣allergies, hypertension and diabetes.

A ⁣Groundbreaking FDA Clearance: Redefining Pediatric OSA Treatment

Last August, Vivos reached ⁤a groundbreaking ‌milestone: the first FDA 510(k)​ clearance for ⁣its proprietary technology. This innovative ​approach offers a safe and effective ‍alternative to traditional surgical interventions,​ providing hope‍ for countless children and their families.For⁤ more facts about Vivos therapeutics and ‍its FDA-cleared technology,⁣ visit [website address].

FDA Clears Groundbreaking​ Device to⁤ Treat ‌Pediatric Sleep Apnea

Littleton, ⁢CO – In a major victory for families struggling with childhood sleep ​apnea, Vivos Therapeutics has received FDA 510(k) clearance for ⁣its Vivos CARE Oral Medical Device to treat moderate to severe obstructive sleep apnea (OSA) in children aged ⁤6 to 17. ‌This innovative, non-surgical solution offers a safe and‌ effective alternative to traditional treatments, ⁤providing hope ⁢for children and peace of mind for parents.OSA,‌ a condition where breathing repeatedly stops and starts ‍during⁢ sleep, affects millions of children, frequently enough leading to daytime fatigue, behavioral​ issues, and even learning difficulties. ‌

“This FDA clearance ⁤is a game-changer‍ for ⁢children suffering from OSA,” said [Insert Name and Title of Vivos representative]. “The Vivos CARE device offers a non-invasive, cozy⁢ solution that addresses the root cause of the problem, allowing children to breathe easier and sleep soundly.”

Clinical trials submitted to ⁤the FDA demonstrated ​the device’s remarkable effectiveness. ‌Ninety-seven percent of adult patients experienced⁤ relief from OSA symptoms, with 80% showing at least a ⁤50% enhancement or a reduction in ⁢severity by one category. ⁢ A remarkable​ 28% achieved full resolution of their OSA. Treatment durations averaged just 9.7 months, with no⁣ need for‍ additional interventions. Similar positive outcomes have been observed in⁤ children.

A Holistic Approach to Breathing and Sleep Health

Vivos Therapeutics, founded in 2016, is dedicated to ‌revolutionizing⁣ the treatment of OSA. The company’s unique approach combines innovative technology ​with a focus on ‌education and partnerships with dentists, functional⁤ medicine doctors, and sleep specialists.

“We believe in empowering healthcare providers to address the complex needs of patients with OSA,” said [Insert Name and Title of Vivos Representative].⁣ “Our goal is to provide a comprehensive solution that not only treats the ⁤symptoms but also improves overall health and well-being.”

The Vivos Method offers a⁢ unique, clinically effective solution‍ that⁢ is non-surgical, non-invasive, and​ non-pharmaceutical. This groundbreaking approach provides hope for patients of all ages, from⁤ children to ⁣adults, who⁢ are seeking⁣ a‍ safe and effective ‌way to manage their ⁣OSA.

For more information about Vivos therapeutics and the Vivos CARE device, please visit [Insert Website Address].

Millions of Americans Could Benefit from​ Untapped Sleep Solution, Says vivos Therapeutics

Vivos Therapeutics, a medical technology company focused ⁢on innovative treatments for sleep‌ apnea, is⁤ highlighting the potential of its non-invasive, FDA-cleared oral appliance therapy to address the widespread issue of sleep-disordered breathing.

The company emphasizes that millions of Americans remain undiagnosed and untreated for sleep apnea, a condition that can have serious health consequences.

“Sleep apnea is ⁤a silent epidemic,” says [Name], CEO of Vivos Therapeutics. “Many people are⁢ unaware they have​ it,‍ and‍ even those ⁤who are diagnosed often ‍struggle to adhere to ⁣traditional treatments like CPAP machines.”

Vivos’s approach⁣ utilizes a customized oral appliance worn during ⁢sleep to gently reposition the jaw and tongue,⁤ opening up the airway and ⁤improving breathing.⁣ This non-invasive ⁢method offers a comfortable and convenient alternative to CPAP, which can be bulky, noisy, and uncomfortable for some users.

The company points to the growing body of research supporting the effectiveness of oral appliance therapy for mild to moderate sleep ​apnea. Studies have shown that these ⁣devices can ⁣considerably reduce apnea events, improve sleep quality, and reduce⁣ daytime⁣ sleepiness.”We believe our technology has‍ the ⁣potential to transform the lives ⁤of millions of Americans‍ suffering from sleep apnea,” says [Name]. “By offering a comfortable ‌and⁤ effective alternative to‍ traditional treatments, we can help people get the restful sleep they need to live healthier, more productive lives.”

Vivos ⁣Therapeutics is committed⁣ to raising awareness about ⁤sleep⁤ apnea ‍and ⁤the benefits of oral appliance ‌therapy. The company is actively working with healthcare⁤ professionals​ to educate them about this innovative treatment⁢ option and make it ⁤more accessible to patients.

​ FDA Clears Revolutionary Non-Surgical Treatment for Pediatric Sleep Apnea

NewsDirectory3.com – (Littleton, CO) – Providing​ a glimmer ⁤of hope for millions​ of children and⁤ their families, Vivos Therapeutics announced today that its Vivos® CARE Oral Medical Device has received FDA 510(k) clearance for the treatment ‍of moderate to ‍severe obstructive sleep apnea (OSA) ‍in children aged 6 to 17. This groundbreaking non-surgical approach marks a ‌important advancement in the field of pediatric healthcare.

We sat down with Kirk Huntsman, CEO of Vivos Therapeutics, to discuss this revolutionary development and its implications for children suffering from OSA.

NewsDirectory3.com: ‌ Mr. Huntsman, congratulations on achieving this crucial FDA clearance. What makes the ⁣Vivos® CARE device⁢ so groundbreaking?

Kirk⁣ Huntsman: Thank ⁤you. This clearance is a culmination of years of research and dedication. Our technology is unique as it offers a safe and effective option to conventional surgical interventions for pediatric ⁤OSA.

The Vivos® CARE device utilizes‌ a custom-fitted⁣ oral appliance that gently expands the upper airway, allowing for improved breathing during sleep.It’s a non-invasive,drug-free treatment that addresses the root cause⁣ of OSA in many children.

NewsDirectory3.com: Why is this development so critically important for children?

Kirk Huntsman: Pediatric OSA is ⁢a serious condition that frequently enough goes undiagnosed and untreated. Children with OSA experience⁤ disrupted sleep,which can ⁤lead to a range of problems,including:

academic difficulties: Fatigue ⁣and poor concentration

Behavioral issues: Increased ​hyperactivity and ​inattention,often mistaken for ADHD

developmental ‌delays: ⁤ Impaired ⁣growth‌ and cognitive function

Long-term health risks: Increased risk of cardiovascular ​disease and other chronic conditions.

Early intervention with the‍ Vivos® CARE device can dramatically improve a child’s quality of ‌life, allowing them to thrive both ‌academically and socially.

NewsDirectory3.com: We understand that Vivos Therapeutics ⁣is committed to⁢ raising awareness about⁢ pediatric OSA. ​Can you elaborate on that?

Kirk Huntsman: Absolutely. Many pediatricians and parents are unaware of the ⁢subtle signs of OSA in children. We’re working to educate‍ healthcare providers and families about the importance of early diagnosis and treatment.

Common symptoms‍ to watch for include​ snoring, mouth breathing, restless sleep,⁤ bedwetting, and daytime fatigue or hyperactivity. If⁣ you notice any of​ these signs, ⁤talk to your child’s doctor.

NewsDirectory3.com: Where can readers⁣ learn more about the Vivos® ⁢CARE device and its‌ availability?

Kirk ⁤Huntsman: They can​ visit our ⁢website at [website address], where they’ll find detailed details about the⁣ technology, FAQs, and a directory of certified Vivos providers.

NewsDirectory3.com: Thank you, Mr. Huntsman, for sharing this important information. ​This FDA clearance represents a significant breakthrough in pediatric healthcare, offering hope and ‍improved quality of life ⁣for countless children and their⁢ families.